Delving into the Latest Updates on Levocetirizine Hydrochloride with Synapse

Overview

Basic Info

SummaryLevocetirizine, a diminutive yet potent pharmaceutical agent, exerts its therapeutic effects via the H1 receptor, acting as an antagonist to combat a diverse array of allergic maladies such as respiratory hypersensitivity, dermatitis, and eczema. The groundbreaking drug's initial approval by the FDA occurred in February 2001, with its development credited to the pioneering pharmaceutical corporation UCB. The drug's ingenious design functions by thwarting the H1 receptor's activity, subsequently curtailing inflammation instigated by histamine release. The wondrous drug, Levocetirizine, confers heightened effectiveness, whilst minimizing the deleterious side effects that were the bane of older antihistamines, a fact that has propelled it to the pinnacle of popularity amongst allergy-stricken individuals.

Drug Type

Small molecule drug

Synonyms

2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid, Airitis, Elzinex

+ [21]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [2]

Active Indication

Respiratory HypersensitivityHypersensitivityPrurigo+ [8]

Inactive Indication

AnaphylaxisAsthmaCough+ [4]

Originator Organization

UCB SA

Active Organization

UCB SA

Chongqing Huapont Pharmaceutical Co. Ltd.UCB Australia Pty Ltd.

+ [2]

Inactive Organization

UCB Pharma GmbHDr. Reddy's Laboratories Ltd. (Russia)UCB Pharma SA

License Organization

GSK Plc

UCB SA

Drug Highest PhaseApproved

First Approval Date

United Kingdom (16 Aug 2001),

Rhinitis, Allergic, PerennialRhinitis, Allergic, SeasonalRhinitis, Allergic+ [1]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H27Cl3N2O3

InChIKeyPGLIUCLTXOYQMV-GHVWMZMZSA-N

CAS Registry130018-87-0

This is a phase II, explorative, open-labeled, multi-centered, double-arm, investigator-initiated clinical trial of Camrelizumab (an anti-PD-1 antibody) in combination with Nab-paclitaxel (a chemotherapeutic agent against breast cancer) and Levocetirizine (an antihistamine) in patients with advanced triple-negative breast cancer. 60 subjects will be enrolled in multiple centers. This study aims to evaluate the effects of Camrelizumab combined with Nab-paclitaxel and Levocetirizine in the treatment of advanced TNBC.

Start Date01 Apr 2025

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

NCT06816784

/ Not yet recruitingPhase 2IIT

COMPARISON OF OUTCOME OF AUTOLOGOUS SERUM THERAPY VS LEVOCETRIZINE IN THE TREATMENT OF CHRONIC URTICARIA

chronic urticaria is one of the most common dermatological disease affecting many people, exploring most treatment options for its treatment is need of an hour.
Our study aim to compare the efficacy of Autologous Serum Therapy (AST) with levocetirizine in Chronic Urticaria patients

Start Date01 Feb 2025

Sponsor / Collaborator

Sheikh Zayed Medical College

100 Clinical Results associated with Levocetirizine Hydrochloride

Login to view more data

100 Translational Medicine associated with Levocetirizine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Levocetirizine Hydrochloride

Login to view more data

1,036

Literatures (Medical) associated with Levocetirizine Hydrochloride

01 Jun 2025·Annals of Medicine and Surgery

DRESS syndrome secondary to phenytoin: a case report and review of the literature

Article

Author: Yadav, Paras ; Sah, Roshan Kumar ; Karki, Sphurna ; Paudyal, Anish ; Thakur, Mukunda ; Dhungana, Sanjay ; Shakya, Rahul ; Bhatta, Sachin ; Poudel, Uday

Introduction and importance::

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially life-threatening skin reaction to certain drugs in susceptible individuals. This is one of the first reported cases of phenytoin-induced DRESS syndrome in Nepal. The long latency period of 6 months since the starting of Phenytoin therapy and the appearance of symptoms of DRESS makes this case unique and thus adds to the existing literature on DRESS.

Case presentation::

A 20-year-old woman with a seizure disorder on phenytoin therapy for 6 months presented with a 2-week history of a pruritic, morbilliform rash involving her limbs, neck, chest, and trunk. Examination revealed bilateral palpable, tender lymphadenopathy over axilla and in left inguinal region. Laboratory investigations demonstrated eosinophilia, elevated leukocyte count, elevated C-reactive protein, and altered liver enzymes. Based on the RegiSCAR criteria, the patient was diagnosed with probable phenytoin-induced DRESS. Initial treatment with oral prednisolone and levocetirizine provided partial relief. Later, Phenytoin was discontinued and replaced with levetiracetam resulting in progressive improvement. The rash and pruritus gradually improved, and corticosteroids were tapered over 2 months.

Clinical discussion::

DRESS presents with fever, rash, eosinophilia, and systemic involvement. Early diagnosis and withdrawal of the offending drug are crucial for managing DRESS. This case underscores the effectiveness of corticosteroids and supportive therapy, highlighting the need for vigilance in patients on anticonvulsants.

Conclusion::

DRESS syndrome should be suspected in patients on antiepileptics presenting with rash, eosinophilia, and systemic involvement. Timely drug withdrawal and corticosteroid therapy are essential for optimal outcomes.

01 Apr 2025·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Considerations of sex in bioequivalence assessments: does sex affect pharmacokinetic variability between evaluation formulations?

Article

Author: Jeong, Seung-Hyun ; Jang, Ji-Hun

BACKGROUND:

Bioequivalence assessment determines the equivalence between drug formulations and is primarily used to demonstrate that a generic product is equivalent to its reference. The sex of the drug consumer is a major consideration in bioequivalence assessment, but specific ratios or absolute criteria for sex composition are usually not specified.

PURPOSE:

This study explored whether the sex of participants in a bioequivalence assessment could significantly affect the pharmacokinetic variability between formulations and decision outcomes. In bioequivalence studies, the sex composition should reflect the drug's target population, but it is often acceptable to limit it to healthy adult males. Therefore, it is essential to consider the variation in bioequivalence results according to sex.

METHODS:

Levocetirizine and rabeprazole enteric-coated tablets were chosen as investigational agents, and clinical trial data for these were used in the bioequivalence analysis. This analysis was conducted both with and without considering sex, and the final determination of equivalence was based on whether the 90% confidence interval for the ratio of standard pharmacokinetic parameters between the reference and test formulations fell within the 80 to 125% range. Additionally, principal component analysis (PCA) was performed to determine whether there were significant differences in the targeted pharmacokinetic parameter values between drug formulations across each sex group.

RESULTS:

Bioequivalence of levocetirizine's reference and test formulations was confirmed, independent of sex. For rabeprazole, bioequivalence was established in males-even without considering sex-but not in females, based on extended criteria for drugs with significant pharmacokinetic variability. The PCA results also showed that there were significant differences (P < 0.05) in the distribution of pharmacokinetic parameters of rabeprazole by gender and formulation. This indicates that equivalence assessments may vary based on pharmacokinetic differences related to sex among subjects in bioequivalence studies. Thus, it was shown that sex may influence pharmacokinetic variability between reference and test formulations of the same drug.

CONCLUSION:

This study provided valuable insights into the role of sex in bioequivalence studies. For drugs exhibiting significant pharmacokinetic differences between sexes, it is crucial to recognize that bioequivalence results may vary based on the sex ratio in the participant group. Therefore, further analysis and interpretation, taking sex-related factors into account, will be necessary during bioequivalence evaluations.

01 Apr 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Development of a stable fixed-dose combination of Montelukast Sodium and Levocetirizine Dihydrochloride using multi-layering API coating technology

Article

Author: Chae, Yu-Byeong ; Lim, Chae-Yong ; Shin, Seo-Young ; Yang, Jung-Ho ; Hwang, Sung-Joo ; Oh, Dong-Joon

PURPOSE:

This study aimed to develop a combination drug containing Montelukast Sodium and Levocetirizine Dihydrochloride using Multi-Layering API Coating Technology (M-LAC Tech) to prevent chemical interactions, enhance stability, and enable sequential drug release.

METHODS:

A core tablet containing Montelukast Sodium was prepared, followed by a barrier coating layer. Levocetirizine Dihydrochloride was then applied as a drug coating over the barrier layer, ensuring complete separation of the two drugs. M-LAC Tech effectively prevents chemical interactions, overcoming the limitations of conventional single-layer and bilayer tablets. An outer coating was added to protect against environmental factors, resulting in a multi-layered film-coated tablet with improved stability and drug release characteristics.

RESULTS:

The developed tablet reduced size by 50% compared to bilayer tablets, improving patient compliance. The barrier coating effectively prevented drug interactions, ensuring stability, while sequential drug release reduced AUC variability and shortened T_max, enhancing absorption and efficacy. Compared to the reference "tablet-in-capsule" formulation, which releases both drugs simultaneously, the M-LAC Tech tablet demonstrated superior pharmacokinetic properties through controlled sequential release.

CONCLUSION:

M-LAC Tech enabled the stable incorporation of two drugs in a single dosage form, achieving the smallest tablet size among similar formulations. The technology's ability to block drug interactions and optimize release profiles provides significant clinical advantages. These findings highlight the potential of M-LAC Tech in advancing combination drug development.

16

News (Medical) associated with Levocetirizine Hydrochloride

16 Jun 2025

·www.prnewswire.com

Cortizone-10® Partners with Dylan Efron and the National Park Foundation to Help Outdoor Enthusiasts Stay Itch-Free This Summer

The brand's new Itch Relief Cooling Spray helps tackle "itchsanity" one irritation at a time. MORRISTOWN, N.J., June 16, 2025 /PRNewswire/ -- Whether it's a weekend hike, a summer camping trip, or just time spent in the backyard, skin irritations can take the fun out of outdoor activities. That's why Cortizone-10®, the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, is teaming up with the National Park Foundation and outdoor advocate Dylan Efron this summer to help more people enjoy nature—without the itch. Continue Reading Dylan Efron with Cortizone-10® Itch Relief Cooling Spray | Photo Credits: brennensmedia Cortizone-10® Itchy Bear Season To enjoy nature without the not-so-great itches, we need to make sure there are outdoor spaces worth enjoying–so Cortizone-10® is partnering with the National Park Foundation, providing $475K as part of a broader brand initiative, to help protect wildlife, preserve habitats, and support conservation efforts across some of the country's most iconic and ecologically rich landscapes. To help amplify the campaign, Dylan Efron—actor, producer, and lifelong outdoor enthusiast—is partnering with Cortizone-10®, an Opella brand, to share his favorite summer adventures and how he doesn't let itches get in the way. "Ever since I was a little kid, I've always loved being outside—all day, every day," said Dylan Efron. "That's why I am so excited to partner with Cortizone-10®. I can't even count how many times I've used this stuff in a year—let alone over my lifetime. Bug bites, poison ivy, poison oak...been there, scratched that. But no itch has ever kept me from enjoying everything the outdoors has to offer." The partnership celebrates the launch of Cortizone-10® 's new Itch Relief Cooling Spray, designed to provide fast, cooling itch relief of common skin irritations that may arise from eczema and psoriasis to bug bites and poison ivy. "We're thrilled to be teaming up with Dylan Efron and the National Park Foundation for a campaign that celebrates adventuring itch-free," said Nimit Bansal, Cortizone-10® Marketing Lead. "Cortizone-10® has always been trusted itch relief for bug bites, eczema, poison ivy, and more—and now, we're making it easier than ever for people to enjoy the outdoors without the itch getting in the way." As part of its broader "Itchsanity" campaign, Cortizone-10® is launching Itchy Bear Season, a social-first series that spotlights different "itchy bear" types one might run into in the great outdoors and shares practical tips on how to stay itch-free outside. A playful nod to natural behaviors seen in the wild, the campaign reminds us that everyone itches—but with Cortizone-10®, you don't have to suffer through it. Visit @cortizone10 on Instagram to cast your vote for itchiest bear in the brand's first-ever Big Bear Itch Off competition and follow along to learn more. The new Cortizone-10® Itch Relief Cooling Spray is available now at drugstores and major retailers nationwide. Learn more at Cortizone10.com. *2024 IQVIA Study About Cortizone-10® Cortizone-10® is the #1 Doctor Recommended OTC Topical Anti-Itch Brand*, trusted for fast, effective relief from itch and irritation. Featuring the maximum strength of hydrocortisone available without a prescription, Cortizone-10® products are specially formulated to calm and soothe a wide range of itchy skin discomforts—including bug bites, poison ivy, eczema, psoriasis, and rashes caused by soaps, detergents, and cosmetics. With a variety of formats like creams, ointments, and sprays, Cortizone-10® delivers targeted, long-lasting relief to help people get back to feeling comfortable—so they can stay focused on what matters most. About Opella Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to put health in people's hands by making self-care as simple as it should be for over half a billion consumers worldwide. At the core of this mission is our 100 brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and four specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of North America's most loved brands, including Allegra®, Dulcolax®, Icy Hot®, Xyzal®, Unisom® and Cortizone-10®. B Corp certified in multiple markets, we are active players in the journey towards healthier people and planet. Find out more about our mission at . SOURCE Cortizone-10® WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

23 May 2025

·www.einpresswire.com

Cetirizine or Levocetirizine: Drug Safety Communication - FDA Warns About Risk of Severe Itching After Discontinuation of Long-Term Use of Allergy Medicines

AUDIENCE: Consumer, Patient, Health Care Professional, Pharmacy, Dermatology ISSUE: The FDA is warning that patients stopping the oral allergy medicines cetirizine (Zyrtec) or levocetirizine (Xyzal) after long-term use may experience rare but severe itching. These medicines are available in prescription and over-the-counter (OTC) forms . The itching, also called pruritus, has been reported in patients who used these medicines daily, typically for at least a few months and often for years. Patients did not experience itching before starting the medicines. Reported cases were rare but sometimes serious, with patients experiencing widespread, severe itching that required medical intervention. As a result, we are revising the prescription cetirizine and levocetirizine prescribing information to include a new warning about this risk. We will subsequently request that manufacturers add a warning about pruritus to the Drug Facts Label of the OTC versions. BACKGROUND: Cetirizine and levocetirizine are antihistamines that block a molecule called histamine that the body releases during allergic reactions. Both medicines are approved to treat seasonal allergies, called seasonal allergic rhinitis, in adults and children 2 years and older. The medicines are also approved to treat year-round allergies, called perennial allergic rhinitis, and chronic hives, called chronic idiopathic urticaria, in patients 6 months and older. Cetirizine was approved for oral use by prescription in December 1995 under the trade name Zyrtec (no longer sold as a prescription medicine) and approved for OTC use in November 2007. Levocetirizine was approved for oral use by prescription in May 2007 under the trade name Xyzal and approved for OTC use in January 2017. RECOMMENDATIONS: Patients Contact your health care professional if you develop severe itching after stopping prescription or OTC cetirizine or levocetirizine. Patients should know that itching typically occurred within a few days of stopping these medicines after daily use for a few months to years. If you are planning on using cetirizine or levocetirizine long term, especially for more than a few months, should discuss the benefits and risks with your health care professional, who can provide advice based on your personal needs. Health Care Professionals Discuss the risk of pruritus after stopping cetirizine or levocetirizine with patients when prescribing or recommending these medicines, especially if planned for chronic use, and with those who indicate they are using OTC versions. Advise patients to contact you if they experience severe itching after stopping cetirizine or levocetirizine. [ FDA Safety Communication - 05/16/2025] Content current as of: 05/23/2025 Regulated Product(s) Topic(s) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalAccelerated ApprovalPatent Expiration

16 May 2025

·www.einpresswire.com

FDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)

Between April 25, 2017, and July 6, 2023, FDA identified 209 cases worldwide (197 domestic) of pruritus after stopping treatment with cetirizine (n=180), levocetirizine (n=27), or both (n=2), in the FDA Adverse Event Reporting System (FAERS) database. In all 209 cases, there was a temporal relationship between discontinuing the medicine and the onset of pruritus, and the median time to onset was 2 days, with a range of 1 to 5 days. Of these reported cases, 87 percent (n=182) were submitted by individuals using the medicines, including 6 self-identified health care professionals reporting their symptoms. In nearly 92 percent (n=97) of the 106 pruritus cases where patients reported time length of medicine usage, the length was more than 3 months, suggesting this timeframe may be a risk predictor. The median duration of medicine use before pruritus occurrence after stopping cetirizine or levocetirizine was 33 months, with a range of 1 week to 23 years. The number of pruritus cases increased with duration of use, suggesting that longer use may increase the risk of this reaction. Many reports described post-discontinuation pruritus over many areas of the body that significantly affected users’ quality of life and ability to function. Serious outcomes included disability (n=48), such as “debilitating itching to the point of being bed-ridden,” hospitalization (n=3), and thoughts of suicide or self-harm (n=2). In 92 of the 93 cases where patients reported one or more attempts at restarting then stopping the medicine, pruritus recurrence occurred. Restarting the medicine resolved pruritus in 71/79 individuals (90 percent) and tapering off the medicine after restarting it resolved symptoms in 9/24 (38 percent) of those who tried this approach. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultClinical StudyDrug Approval

100 Deals associated with Levocetirizine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08118	-	R06AE09	DB06282

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Respiratory Hypersensitivity	United States	Chattem, Inc.	31 Jan 2017
Hypersensitivity	Japan	GSK Plc	31 Oct 2010
Prurigo	Japan	GSK Plc	27 Oct 2010
Chronic Urticaria	China	UCB SA	20 Oct 2005
Dermatitis	China	Chongqing Huapont Pharmaceutical Co. Ltd.	21 Jan 2004
Eczema	China	Chongqing Huapont Pharmaceutical Co. Ltd.	21 Jan 2004
Pruritus	China	Chongqing Huapont Pharmaceutical Co. Ltd.	21 Jan 2004
Rhinitis, Allergic	Austria	UCB SA	16 Aug 2001
Rhinitis, Allergic	Belgium	UCB SA	16 Aug 2001
Rhinitis, Allergic	Cyprus	UCB SA	16 Aug 2001
Rhinitis, Allergic	Czechia	UCB SA	16 Aug 2001
Rhinitis, Allergic	Denmark	UCB SA	16 Aug 2001
Rhinitis, Allergic	Estonia	UCB SA	16 Aug 2001
Rhinitis, Allergic	Finland	UCB SA	16 Aug 2001
Rhinitis, Allergic	France	UCB SA	16 Aug 2001
Rhinitis, Allergic	Germany	UCB SA	16 Aug 2001
Rhinitis, Allergic	Greece	UCB SA	16 Aug 2001
Rhinitis, Allergic	Hungary	UCB SA	16 Aug 2001
Rhinitis, Allergic	Ireland	UCB SA	16 Aug 2001
Rhinitis, Allergic	Italy	UCB SA	16 Aug 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anaphylaxis	Phase 3	-	UCB Pharma GmbH	01 Aug 2003
Asthma	Phase 3	-	UCB Pharma SA	20 Mar 2002
Dermatitis, Atopic	Phase 3	-	UCB Pharma SA	20 Mar 2002
Cough	Phase 2	-	UCB Pharma GmbH	01 Dec 2001
Pruritis (itchy skin)	Phase 1	China	Chongqing Huapont Pharmaceutical Co. Ltd.	12 Sep 2017
Perennial allergic rhinitis with seasonal variation	Phase 1	Japan	GSK Plc	02 May 2012
Fasting	Phase 1	India	Dr. Reddy's Laboratories Ltd. (Russia)	01 Dec 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03555890 (CTgov)	Phase 1	Rhinitis	72	Levocetirizine (Part 1: Levocetirizine ODT 5 mg)	zejvugnnkj(oqldecvfpo) = kzkopiqsso znrhxkjxvw (vusdigzlvf, pqngwczixq - wtvznbekjq) View more	-	12 Sep 2019
				Levocetirizine (Part 1: Levocetirizine IRT 5 mg)	zejvugnnkj(oqldecvfpo) = lfnhhpfzoa znrhxkjxvw (vusdigzlvf, ggiuebqddl - ffjoyjwyvg) View more
NCT01722162 (CTgov)	Phase 2	Refractory Colorectal Carcinoma	47	Levocetirizine+Bevacizumab+capecitabine (Arm A: (Start Levocetirizine After Bevacizumab/Capecitabine))	eqauamsdyj = qbpbvxptzs bgmvvnvetr (xwfdyfspbj, ojojztxhbl - wujjascpnq) View more	-	13 Feb 2017
				Levocetirizine+Bevacizumab+capecitabine (Arm B: (Start Levocetirizine Before Bevacizumab/Capecitabine))	igpqizrsgx = eamavexewy xevzxbiawo (xdiopabqzt, qdfuuspjbl - tvbxnyttfj) View more
NCT01722162 (ASCO_GI2015) Manual	Phase 2	Metastatic Colorectal Carcinoma	36	levocetirizine+capecitabine+bevacizumab	oavotqxkxt(xylbrvhkyd) = prxpgkrmjd ddlvjndtjz (kplpzeodiq ) View more	Positive	20 Jan 2015
NCT01622283 (Pubmed \| J Drug Assess)	Phase 1	-	20	Levocetirizine oral solution 5mg	ivzcwlflbk(vxummlekpd) = hcvhodbmwk dmtxjlljvb (atzbjsoatl ) View more	-	01 Jan 2014
				Cetirizine dry syrup 10mg	ivzcwlflbk(vxummlekpd) = ssfnzhzlge dmtxjlljvb (atzbjsoatl ) View more
NCT00884325 (CTgov)	Phase 4	Pruritus \| Dermatitis, Atopic	40	Xyzal (Subjects Receiving Xyzal)	uhtblurhjv(uxbtcqcvcm) = ewvcvqamtq qqpztfzjli (ctbafqkvyo, ifqqjytsjd - jtpzolytyd) View more	-	16 Aug 2013
				Placebo (Subjects Receiving Placebo)	uhtblurhjv(uxbtcqcvcm) = qkegubhsoh qqpztfzjli (ctbafqkvyo, qjaziiaaaq - sossxfkgse) View more
NCT01563081 (CTgov)	Phase 3	Pruritus \| Rhinitis, Allergic	60	Levocetirizine (Levocetirizine: >=6 Months and <12 Months Old)	lfisjcrmkh = defxxlmlwb pohsqqecik (kpcczprcne, acndpqorna - kwnzgmyows) View more	-	03 Jun 2013
				Levocetirizine (Levocetirizine: >=12 Months and <24 Months Old)	lfisjcrmkh = bqxvnxocdx pohsqqecik (kpcczprcne, sripmbmyrx - wdjnwypczp) View more
AAAAI2011	Not Applicable	Rhinitis, Allergic	-	Levocetirizine	rwlauncoal(jfkxmdofiq) = pljwxrtwlg yihikmtihb (zfaqpomfuk, -8.1% - -7.9%) View more	Positive	01 Feb 2011
AAAAI2010	Not Applicable	Rhinitis, Allergic, Perennial nNO \| nEos	31	Oral Levocetirizine (LC) 5mg	laiqldqbft(ghxyanlmsl) = rpawxzrnhd wiaoveknmf (erqgzplgbo )	Positive	01 Feb 2010
NCT00653224 (CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	580	placebo	omhwhidoss(dagcvcozmf) = gewboxssqn mxaopemmny (bfbzpoxlyp, 3.44) View more	-	17 Nov 2009
NCT00375713 (CTgov)	Phase 3	Eczema	466	Placebo-Cetirizine+Levocetirizine+Standard topical steroid (1% hydrocortisone) ointment (Levocetirizine)	fnzvdrnrdx = maihbgqxzc lkgcbohcjw (jpoysnscxi, yolzbxsdau - jbugheghft) View more	-	14 Oct 2009
				Placebo-Levocetirizine+Cetirizine+Standard topical steroid (1% hydrocortisone) ointment (Cetirizine)	fnzvdrnrdx = bfsilpibpl lkgcbohcjw (jpoysnscxi, xpehxgsrkx - wjllhwpiaj) View more